Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Net Margin (2016 - 2025)

Vistagen Therapeutics' Net Margin history spans 12 years, with the latest figure at 6237.29% for Q4 2025.

  • For Q4 2025, Net Margin fell 21635.0% year-over-year to 6237.29%; the TTM value through Dec 2025 reached 8486.84%, down 332116.0%, while the annual FY2025 figure was 10579.84%, 782025.0% down from the prior year.
  • Net Margin for Q4 2025 was 6237.29% at Vistagen Therapeutics, up from 7525.97% in the prior quarter.
  • Across five years, Net Margin topped out at 90900.0% in Q1 2025 and bottomed at 12777.38% in Q2 2024.
  • The 4-year median for Net Margin is 3678.77% (2021), against an average of 1527.5%.
  • The largest annual shift saw Net Margin crashed -932588bps in 2024 before it skyrocketed 9003274bps in 2025.
  • A 4-year view of Net Margin shows it stood at 3000.56% in 2021, then soared by 49bps to 1545.01% in 2023, then tumbled by -290bps to 6020.94% in 2024, then decreased by -4bps to 6237.29% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Net Margin are 6237.29% (Q4 2025), 7525.97% (Q3 2025), and 6186.48% (Q2 2025).